Table 2.
Primary and secondary analyses
| Number of studies | Number of patient | AUC ROC | 95%CI | OR | 95%CI | Tau2 | I2 | P value | |
|---|---|---|---|---|---|---|---|---|---|
| Primary analysis (Mortality in ACF patients) | 13 | 1038 | 0.66 | [0.59; 0.76] | 3.4 | [1.4; 8.3] | 1.4 | 79% | 0.013 |
| Secondary analysis (Mortality or adverse event in patients at risk or confirmed ACF) | 23 | 59,522 | 0.69 | [0.65; 0.74] | 4.3 | [2.6; 7.3] | 0.9 | 96% | < 0.001 |
| Secondary analysis (Comparison of CRT and Lactate) | |||||||||
| CRT | 9 | 7023 | 0.68 | [0.60; 0.79] | 3.2 | [1.1; 9.1] | 0.7 | 77% | 0.687 |
| Lactate | 9 | 7023 | 0.54 | [0.53; 0.55] | 2.6 | [1.3; 5.2] | 0.8 | 81% | |
ACF Acute circulatory failure, AUC ROC Area under the curve of the receiver operating characteristic CI Confidence interval, OR Odds ratio. P value stands for the P value the effect size with the random effect model for the two first analysis and the comparison of the effect size between lactate and CRT in the last analysis